Overview

A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection

Status:
Terminated

Trial end date:
2016-12-01

Target enrollment:

Participant gender:

Summary

Patients with HBeAG positive, chronic HBV infection will receive either ARC-520 or placebo in combination with entecavir or tenofovir, and be evaluated for safety and efficacy.

Phase:

Phase 2

Details

Lead Sponsor:

Arrowhead Pharmaceuticals

Treatments:

Entecavir
Histamine Antagonists
Histamine H1 Antagonists
Tenofovir